Amendment: SEC Form F-6/A filed by BeiGene Ltd.
As filed with the Securities and Exchange Commission on May 1, 2025 |
Registration No. 333 – 286725 |
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
__________________________________
pre-effective amendment no. 1 to fORM F-6
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933 FOR AMERICAN DEPOSITARY SHARES EVIDENCED BY
AMERICAN DEPOSITARY RECEIPTS
______________
BeOne Medicines Ltd.
(Exact name of issuer of deposited securities as specified in its charter)
______________
N/A
(Translation of issuer’s name into English)
______________
Switzerland
(Jurisdiction of incorporation or organization of issuer)
__________________________________
CITIBANK, N.A.
(Exact name of depositary as specified in its charter)
______________
388 Greenwich Street
New York, New York 10013
(877) 248-4237
(Address, including zip code, and telephone number, including area code, of depositary’s principal executive offices)
______________
Cogency Global Inc.
122 East 42nd Street, 18th Floor
New York, New York 10168
(800) 221-0102
(Address, including zip code, and telephone number, including area code, of agent for service)
__________________________________
Copies to:
|
Mitchell S. Bloom, Esq. Edwin M. O’Connor, Esq. Marishka DeToy, Esq. Goodwin Procter LLP 100 Northern Avenue Boston, MA 02210 (617) 570-1000 |
John V. Oyler Chief Executive Officer and Chairman c/o Mourant Governance Services (Cayman) Limited 94 Solaris Avenue, Camana Bay Grand Cayman Cayman Islands KY1-1108 (345) 949-4123 |
Herman H. Raspé, Esq. Patterson Belknap Webb & Tyler LLP |
__________________________________
| It is proposed that this filing become effective under Rule 466: | ☐ immediately upon filing. |
| ☐ on (Date) at (Time). | |
| If a separate registration statement has been filed to register the deposited shares, check the following box: ☒ | |
__________________________________
CALCULATION OF REGISTRATION FEE
| Title of Each Class of Securities to be Registered |
Amount to be Registered |
Proposed Maximum Aggregate Price Per Unit* |
Proposed Maximum Aggregate Offering Price** |
Amount of Registration Fee |
| American Depositary Shares (“ADS(s)”), each ADS representing the right to receive thirteen (13) ordinary shares of BeOne Medicines Ltd. (the “Company”) | N/A | N/A | N/A | N/A |
| * | Each unit represents 100 ADSs. |
| ** | Estimated solely for the purpose of calculating the registration fee. Pursuant to Rule 457(k), such estimate is computed on the basis of the maximum aggregate fees or charges to be imposed in connection with the issuance of ADSs. |
| The Registrant hereby amends this Registration Statement on Form F-6 on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement on Form F-6 shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, or until this Registration Statement on Form F-6 shall become effective on such date as the United States Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine. | |
This Pre-Effective Amendment No. 1 to Registration Statement on Form F-6 may be executed in any number of counterparts, each of which shall be deemed an original, and all of such counterparts together shall constitute one and the same instrument.
PART I
INFORMATION REQUIRED IN PROSPECTUS
Cross Reference Sheet
| Item 1. | DESCRIPTION OF SECURITIES TO BE REGISTERED |
Item Number and Caption
|
Location in Form of American Depositary Receipt (“Receipt”) | |||
| 1. | Name of Depositary and address of its principal executive office | Face of Receipt - Introductory Article. | ||
| 2. | Title of Receipts and identity of deposited securities | Face of Receipt - Top Center. | ||
| Terms of Deposit: | ||||
| (i) | The amount of deposited securities represented by one American Depositary Share (“ADSs”) | Face of Receipt - Upper right corner. | ||
| (ii) | The procedure for voting, if any, the deposited securities | Reverse of Receipt - Paragraphs (17) and (18). | ||
| (iii) | The collection and distribution of dividends | Reverse of Receipt - Paragraph (15). | ||
| (iv) | The transmission of notices, reports and proxy soliciting material | Face of Receipt - Paragraph (14); Reverse of Receipt - Paragraph (18). | ||
| (v) | The sale or exercise of rights |
Reverse of Receipt – Paragraphs (15) and (17). | ||
| (vi) | The deposit or sale of securities resulting from dividends, splits or plans of reorganization |
Face of Receipt - Paragraphs (3) and (6); Reverse of Receipt - Paragraphs (15) and (17). | ||
| (vii) | Amendment, extension or termination of the deposit agreement | Reverse of Receipt - Paragraphs (23) and (24) (no provision for extensions). | ||
| (viii) | Rights of holders of Receipts to inspect the transfer books of the Depositary and the list of holders of ADSs | Face of Receipt - Paragraph (14). | ||
| (ix) | Restrictions upon the right to deposit or withdraw the underlying securities | Face of Receipt – Paragraphs (2), (3), (4), (6), (7), (9) and (10). | ||
I-1
Item Number and Caption |
Location in Form of American Depositary Receipt (“Receipt”) | |||
| (x) | Limitation upon the liability of the Depositary |
Face of Receipt - Paragraph (8); Reverse of Receipt - Paragraphs (20) and (21). | ||
| 3. | Fees and charges which may be imposed directly or indirectly on holders of ADSs | Face of Receipt - Paragraph (11). | ||
| Item 2. | AVAILABLE INFORMATION | Face of Receipt - Paragraph (14). | ||
The Company is subject to the periodic reporting requirements of the United States Securities Exchange Act of 1934, as amended, and, accordingly, files certain reports with, and submits certain reports to, the United States Securities and Exchange Commission (the “Commission”). These reports can be retrieved from the Commission’s internet website (www.sec.gov), and can be inspected and copied at the public reference facilities maintained by the Commission at 100 F Street, N.E., Washington D.C. 20549.
I-2
PROSPECTUS
The Prospectus consists of the proposed form of American Depositary Receipt included as Exhibit A to the Form of Deposit Agreement filed as Exhibit (a)(i) to this Pre-Effective Amendment No. 1 to Registration Statement on Form F-6 and is incorporated herein by reference.
I-3
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
| Item 3. | EXHIBITS |
| (a)(i) | Form of Amended and Restated Deposit Agreement, by and among BeOne Medicines Ltd. (the “Company”), Citibank, N.A., as depositary (the “Depositary”), and all Holders and Beneficial Owners of American Depositary Shares issued thereunder. ___ Filed herewith as Exhibit (a)(i). |
| (a)(ii) | Amendment No. 1 to Deposit Agreement, dated as of April 11, 2016, by and among BeiGene Ltd., the Depositary, and all Holders and Beneficial Owners of American Depositary Shares issued thereunder. ___ Previously filed as exhibit (a)(ii) to Registration Statement on Form F-6, Reg. No. 333-286725, filed on April 24, 2025, and incorporated herein by reference. |
| (a)(iii) | Deposit Agreement, dated as of February 5, 2016, by and among BeiGene Ltd., the Depositary, and all Holders and Beneficial Owners of American Depositary Shares issued thereunder. ___ Previously filed as exhibit (a)(ii) to Registration Statement on Form F-6 (Reg. No. 333-209044), filed with the Securities and Exchange Commission on March 31, 2016, and incorporated herein by reference. |
| (b)(i) | Form of Amended and Restated Restricted ADS Letter Agreement by and between the Company and the Depositary. ___ Filed herewith as Exhibit (b)(i). |
| (b)(ii) | Form of Amended and Restated Letter Agreement by and between the Company and the Depositary (Listing of BeOne Medicines Ltd. Shares in Hong Kong). ___ Filed herewith as Exhibit (b)(ii). |
| (b)(iii) | Form of Amended and Restated Supplemental Letter Agreement by and between the Company and the Depositary. ___ Filed herewith as Exhibit (b)(iii). | |
| (b)(iv) | Supplemental Letter Agreement, dated as of December 30, 2019, by and between BeiGene Ltd. and the Depositary. ___ Previously filed as exhibit (b)(iv) to Registration Statement on Form F-6, Reg. No. 333-286725, filed on April 24, 2025, and incorporated herein by reference. |
| (b)(v) | Letter Agreement, dated as of August 2, 2018, by and between BeiGene Ltd. and the Depositary (Listing of BeiGene Ltd. Shares in Hong Kong). ___ Previously filed as exhibit (b)(v) to Registration Statement on Form F-6, Reg. No. 333-286725, filed on April 24, 2025, and incorporated herein by reference. | |
| (b)(vi) | Restricted ADS Letter Agreement, dated as of July 11, 2016, by and between BeiGene Ltd. and the Depositary. ___ Previously filed as exhibit (b)(vi) to Registration Statement on Form F-6, Reg. No. 333-286725, filed on April 24, 2025, and incorporated herein by reference. |
II-1
| (c) | Every material contract relating to the deposited securities between the Depositary and the issuer of the deposited securities in effect at any time within the last three years. ___ None. |
| (d) | Opinion of counsel for the Depositary as to the legality of the securities to be registered. ___ Previously filed as exhibit (d) to Registration Statement on Form F-6, Reg. No. 333-286725, filed on April 24, 2025, and incorporated herein by reference. |
| (e) | Certificate under Rule 466. ___ None |
| (f) | Powers of Attorney for certain officers and directors and the authorized representative of the Company. ___ Set forth on the signature pages to Registration Statement on Form F-6, Reg. No. 333-286725, filed on April 24, 2025, and incorporated herein by reference. |
II-2
| Item 4. | UNDERTAKINGS |
| (a) | The Depositary undertakes to make available at the principal office of the Depositary in the United States, for inspection by holders of ADSs, any reports and communications received from the issuer of the deposited securities which are both (1) received by the Depositary as the holder of the deposited securities, and (2) made generally available to the holders of the underlying securities by the issuer. |
| (b) | If the amount of fees charged is not disclosed in the prospectus, the Depositary undertakes to prepare a separate document stating the amount of any fee charged and describing the service for which it is charged and to deliver promptly a copy of such fee schedule without charge to anyone upon request. The Depositary undertakes to notify each registered holder of an ADS thirty (30) days before any change in the fee schedule. |
II-3
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, Citibank, N.A., acting solely on behalf of the legal entity to be created by the Deposit Agreement, by and among BeOne Medicines Ltd., Citibank, N.A., as depositary, and all Holders and Beneficial Owners from time to time of American Depositary Shares to be issued thereunder, certifies that it has reasonable grounds to believe that all the requirements for filing on Form F-6 are met and has duly caused this Pre-Effective Amendment No. 1 to Registration Statement on Form F-6 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York, on the 1st day of May, 2025.
| Legal entity created by the Deposit Agreement under which the American Depositary Shares registered hereunder are to be issued, each American Depositary Share representing the right to receive thirteen (13) ordinary shares of BeOne Medicines Ltd. | ||
| CITIBANK, N.A., solely in its capacity as Depositary | ||
| By: | /s/ Joseph Connor | |
| Name: Joseph Connor | ||
| Title: Attorney-in-Fact | ||
II-4
signatures
Pursuant to the requirements of the Securities Act of 1933, as amended, BeOne Medicines Ltd. certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on this Pre-Effective Amendment No. 1 to Registration Statement on Form F-6 and has duly caused this registration statement to be signed on its behalf by the undersigned thereunto duly authorized, in the City of New York, State of New York, on May 1, 2025.
| BeOne Medicines Ltd. | ||
| By: | /s/ Chan Lee | |
| Name: Chan Lee | ||
| Title: Senior Vice President, General Counsel | ||
II-5
Pursuant to the requirements of the Securities Act of 1933, as amended, BeOne Medicines Ltd. certifies that it has reasonable grounds to believe that all requirements for filing on Form F-6 are met and has duly caused this Pre-Effective Amendment No. 1 to Registration Statement on Form F-6 to be signed on its behalf by the undersigned thereunto duly authorized, in the City of New York, State of New York, on May 1, 2025.
| Signature | Title | |
| /s/ John V. Oyler | Chief Executive Officer and Chairman | |
| John V. Oyler | (Principal Executive Officer) | |
| /s/ Aaron Rosenberg | Chief Financial Officer | |
| Aaron Rosenberg | (Principal Financial Officer) | |
| /s/ Titus Ball | Chief Accounting Officer | |
| Titus Ball | (Principal Accounting Officer) | |
| * | ||
| Olivier Brandicourt | Director | |
| * | ||
| Margaret Dugan | Director | |
| * | ||
| Michael Goller | Director | |
| * | ||
| Anthony C. Hooper | Director | |
| * | ||
| Ranjeev Krishana | Director | |
| * | ||
| Alessandro Riva | Director | |
| * | ||
| Corazon (Corsee) D. Sanders | Director |
II-6
| Signature | Title | |
| * | ||
| Xiaodong Wang | Director | |
| * | ||
| Qingqing Yi | Director | |
| * | ||
| Shalini Sharp | Director |
| * Attorney-in Fact | ||
| By: | /s/ Chan Lee | |
| Name: Chan Lee | ||
| Title: Attorney-in-Fact | ||
II-7
SIGNATURE OF AUTHORIZED REPRESENTATIVE IN THE UNITED STATES
Pursuant to the requirements of Section 6(a) of the Securities Act of 1933, the undersigned has signed this Pre-Effective Amendment No. 1 to Registration Statement on Form F-6, solely in its capacity as the duly authorized representative of BeOne Medicines Ltd., in the City of New York, State of New York, on May 1, 2025.
| Authorized U.S. Representative | ||
| BeOne Medicines USA, Inc. | ||
| By: | /s/ Chan Lee | |
| Name: Chan Lee | ||
| Title: Senior Vice President, General Counsel | ||
II-8
Index to Exhibits
| Exhibit | Document |
Sequentially Numbered Page |
| (a)(i) | Form of Amended and Restated Deposit Agreement | |
| (b)(i) | Form of Amended and Restated Restricted ADS Letter | |
| (b)(ii) | Form of Amended and Restated Letter Agreement | |
| (b)(iii) | Form of Amended and Restated Supplemental Letter Agreement |
II-9